醫藥 - BTBA 1/6 CABA 1/19

JANBTBA-Boston Taiwanese Biotechnology Association
BTBA January Seminar: Mao-Lun Weng and Hai-Yin Wu
Sunday, January 6, 2019 at 2:15 PM – 3:30 PM
Room 119/121 MIT Building 25, 45 Carleton Street, Cambridge, MA 02142
Kick-start the year of 2019 by joining us in the January Seminar! Mao-Lun will present his work on how the change in the organelle-nuclear interactions may lead to speciation and increase biodiversity, and Hai-Yin will share with us her work on spindle positioning and oscillation. Light refreshments will be provided.
About BTBA-Boston Taiwanese Biotechnology Association
Biotechnology Company
BTBA builts the Taiwanese bioscientist community by holding symposiums, academic seminars, career panels, and more.

Original Jo Lee CABA 1214
10th MDDI
Saturday, January 19, 2019
860 Winter St, Waltham, MA 02451
The 10th CABA Medical Device and Diagnostics Innovation Symposium (MDDI), co-sponsored by NECINA and HMS CSSA, is scheduled for Saturday, January 19, 2019 at theConference Center at Waltham Woods, 860 Winter St, Waltham, MA 02451.  
The annual CABA MDDI Symposium is a major event attracting prominent entrepreneurs, investors, biotech and executives, academic and industry scientists, as well as professionals from the legal, finance, and healthcare fields from locally and internationally. Past symposiums were extremely well attended. More than 200professional attendees will be expected.
9th MDDI in 2017 was well attended
The theme of this symposium is Innovating for better life. Topics of this years symposium will include novel innovations happened in medical device and diagnostics fields, unique entrepreneurial experience, perspective of investment institute, and understanding of current US-China policy etc. 
Featured Topics
·       Next Generation Innovations for Medical Device & Diagnostics
·       Vision of How AI Technology Changes Our Future and Better Healthcare Service
·       Digital Pathology Solution from Wyss Institute    
·       Innovation for Single Cell Sequencing    
·       Diagnostics Driven by CRISPR    
·       Novel Diagnostics Platform, with Exosome Probe       
·       NMPA (CFDA) Expert Insights of China Healthcare Regulatory  
·       Novel Microfluidics Solution for Healthcare    
·       Rosalind Picard(TBD), Professor of MIT; Faculty Chair of MIT Media Lab
·       Michael J.Natan, CEO of Ultivue    
·       Rong Fan, Professor of Yale University, Co-founder of SingleRon and  IsoPlexis    
·       Omar Abudayyeh, Co-CEO of SHERLOCK-based Startup    
·       Thomas McLain, General Manager of ExosomeDx, a Boston startup acquired with $500+ valuation    
·       Huang Yiwu, Deputy Director of Shanghai Municipal Food and Drug Administration
·       Larry Alberts, CEO and Co-founder of Cam Med    
·       Shuguang Zhang, Associate Directorof the Center for Biomedical Engineering, MIT
Boston Scientific
More Health
PKI Ventures
Frees Capital

Email: Ben.Wei@cabaweb.org
More information: www.cabaweb.org

MDDI Symposium
  Regular: $40 
  Student: $20
  Active CABA Member: Free

  Regular: $100
  Student: $60

Register Now
*Use the QR code above or click "read more" to visit the registeration page, thank you!
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.
Chinese-American BioMedical Association

- 借助药明生物自主开发的超高效连续细胞培养生产工艺平台WuXiUP,运用1000升一次性生物反应器生产单克隆抗体可以达到与10000升至20000升传统不锈钢生物反应器相当的批次产量
- WuXiUP平台在实现高产量的同时保证了媲美传统纯化工艺的高纯化收率
上海,2018年12月12日——全球领先的开放式生物制药技术平台公司药明生物(WuXi Biologics, 2269.HK)今日宣布公司在一款抗体Fc融合蛋白产品产率上取得突破性进展。凭借药明生物自主开发的超高效连续细胞培养生产工艺平台WuXiUP(WuXi Ultra-high Productivity),该产品日平均产量达到2.5克/升,20天连续生产批次产量高达51克/升,是传统细胞培养批次产量3至5克/升的十倍以上。目前,该技术正在放大至GMP生产阶段,并将应用于药明生物位于中国无锡和上海、爱尔兰、新加坡和美国的生产基地,助力公司打造健全强大的全球供应链网络。


BTBA Special Talk: National Taiwan University AI Center
Saturday, December 1, 2018 at 10:00 AM – 12:00 PM EST
MIT Building E25; Room 119/121
BTBA Special Talk: We are the honor to invite Dr. George Tseng to give us an introduction of National Taiwan University (NTU) - Artifical Intelligence (AI) Innovation Research Center. This NTU-AI center was founded in 2018 and under Taiwan's Ministry of Science and Technology (MOST; 科技部). The Center is composed of two sub-centers: 1). Artificial Intelligence Technology sub-center and 2). All Vista Healthcare sub-center. Please come to join us for enjoying this BTBA special talk to know the Technology development in Taiwan! 

BTBA 特別演講:這次我們邀請到台大人工智慧中心 (NTU-AI Center) 的曾柏元 副執行長,來跟大家介紹科技部在2018成立的台大人工智慧中心!此中心的全名為人工智慧技術暨全幅健康照護聯合研究中心,簡稱台大人工智慧中心或台大AI中心,包括智慧技術和生技醫療兩個主題、人工智慧技術及全幅健康照護兩個子中心。歡迎大家一起來聆聽並了解一下台灣目前的科技發展

BTBA December Seminar: Ariel Yeh and Chen-Yu Wang

  • Sunday, December 2, 2018 at 2:15 PM – 3:30 PM
  • Room 119/121, MIT Building 25, 45 Carleton Street, Cambridge, MA 02142
Join us for the last seminar this year! We have two brilliant speakers from two very hot research fields! Ariel will share about the latest technology in the genome editing field and introduce companies focusing on CRISPR tools. Chen-Yu will share his work in dissecting the mechanism of X chromosome inactivation, which is a paradigm in studying the role of long noncoding RNAs in epigenetic regulation.
Light refreshments will be served. See you on 12/2!
2018年最後一場seminar,由兩位傑出的講者帶來兩個熱門領域的最新研究。Ariel 將會告訴我們CRISPR領域最新的發展,而Chen-Yu 將會與我們分享細胞如何運用 long non-coding RNA 關閉其中一條 x 染色體的表現。現場備有簡易點心,歡迎大家在2018年的尾聲來聚聚!

著名的中医专家张季教授、中医科研专家李秀敏教授、中药颗粒剂专家天江药业总裁俞敏及Eric Brand博士将于11/11/2018莅临2018 哈佛中医药论坛暨天江中药配方颗粒学术论坛讲课。此次论坛将授予九个学分,收费(包括午餐)会员仅$60、非会员$90,哈佛Faculty, Fellow, Students 免费(需出示哈佛ID), 

ISCT publishes annual report on cell and gene therapy market authorisations

Report to enable patients and entire cell therapy community to identify treatments approved by government regulatory authorities

Vancouver, Canada, November 20, 2018 – ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces the first publication of its new annual report detailing global cell and gene therapies (CGT) with market authorization.

The CGT market authorization report is intended to provide a centralized resource and increased clarity for all of those involved in the CGT industry. This involves the scientific community, healthcare stakeholders and patient associations. The report will be a regularly updated document that will be republished yearly, and accessible through the ISCT website, www.celltherapysociety.org, and www.isct-unprovencellulartherapies.org.  

The report has been designed to react to the increase in momentum around a widening number of CGT authorizations, as well as a parallel increase of unproven approaches where cells are delivered as treatments without rigorous scientific and regulatory assessment and authorization. 

The report has been prepared by select members of the ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell & Gene Therapies (UCGT) with lead authors Natividad Cuende (Executive Director, Andalusian Initiative for Advanced Therapies, Seville, Spain) and Laertis Ikonomou (Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA). The ISCT Presidential Task Force was formed in 2014 to support ISCT’s ongoing commitment to address the rise of commercially available unproven or insufficiently proven CGT treatments. These approaches are targeted at hopeful individuals seeking cures or health improvement for a variety of conditions. The PTF-UCGT characterizes unproven cellular interventions and promotes safe and effective practices worldwide. 

The reliable, up-to-date resource will help patients to make informed decisions before receiving a CGT treatment so that they can avoid being exposed to unproven and unlicensed cell interventions not approved by a regulatory or medicine agency.

The report also provides an annual breakdown of CGTs that have received, as well in some cases, have withdrawn, market approval. This includes analysis on types of product and therapy as well as disease targeted. 44 unique products were identified. 84% were cell and tissue therapies, and 55% were autologous. More than one third target oncological or hematologic conditions. 

In the US, there are over 16 cell, tissue and gene products with marketing authorization, 14 in Korea, eight in Europe, four in India and Japan, two in Canada, and one each in China and Australia. This contrasts with Russia, Middle East, Africa, Central and South America, which have no CGT market authorizations or data available. 

“The number of market approved cell and gene therapy treatments continues to grow, with a high number of other therapies seeking approval. It is critical for all those involved in the sector, and most importantly those patients that may benefit from newly approved treatments, to have an annually updated resource detailing all approved cell and gene therapies,” said Massimo Dominici, Chair of the ISCT Presidential Task Force on Unproven and Unethical Cell & Gene Therapies. “This resource will give patients visibility on what cell and gene therapies have gone through proper approval processes, and help them alongside physicians to make more informed decisions about their treatment.”

In tandem with the efforts of professional societies like ISCT, it is imperative that the regulatory environment and guidance keep pace with the rapid advancements in cell and gene therapy. As such, this report also supports ISCT the FDA’s continued publication of numerous draft CGT guidance documents in 2018.

2018 Harvard TCM & Tianjiang Granule Extracts Forum
Time: 8:45am-6:00pm Sunday November 11, 2018
Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,
MA 02478
Parking: Free
CEUs (Continue Education Credit): 9 credits
Fee (lunch included): Members $60, none members $90
Free for Dr. Lee’s group, Harvard Faculty/Fellow (NO CEU, reservation
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS
Supported: Tianjiang Pharmaceuticals. CO.
8:45-9:15am Registration
9:15-11:30am 七方理論臨床運用心得 张季
Experience in Clinical Application of Seven Formulas Theory dr.
Ji Zhang PhD, L.Ac
11:30-12:10pm Traditional Chinese Medicine, Western Science, and the Search
for a Cure for Allergies
Prof. Xiumin Li, MD New York Medical College
12:10-12:50pm 天江中药配方颗粒研究进展 俞敏 天江药业总经理
Progress on Tianiiang Granule Extracts Research Min Yu, CEO of Tiangjiang
Pharmaceuticals. Co.
12:50-2:10pm Lunch & discussion

2018 哈佛醫學院中醫藥論壇
2:10pm-2:40pm 配方颗粒的国际趋势:标准与临床特点 Eric Bran PhD
Global Trends in Granule Extracts: Standards and Clinical Styles Eric Bran
2:40-5:40pm 升陽益氣諸方劑在脾胃病的應用體會
Application Experience of Yang-raising and Qi-augmenting Formulas in
Spleen-Stomach Diseases Dr. Ji Zhang, PhD, L.Ac
5:40-6:00pm Discussion
Call Dr. Li 617 323 7809 or
1. 七方理論臨床運用心得
2. 升陽益氣諸方劑在脾胃病的應用體會
張季,1978 年入學南京中醫藥大學中醫系,1983 年畢業後旋即留校任教,曾師從各家學說大家丁
辭典》等10 餘部學術著作,其中多部獲獎。1992 年來美,又在美國獲DAOM 博士學位。張季中
醫師至今已在中美兩地臨床35 年,應用中藥方劑辨證施治,經驗豐富,對脾胃病、肝膽病、婦科
1995 年起,先後執教於洛杉磯多家中醫院校碩士班和博士班。近年來,多次在美國各地中醫公會
俞敏,男,1973 年6 月出生,长江商学院EMBA 硕士,高级经济师,江苏省中药饮片研究专委会
常委副主委,现任江阴天江药业有限公司总经理。江阴天江药业有限公司成立于1992 年,隶属于
Xiu-Min Li, M.D., M.S.. Dr. Li obtained her MD degree in Henan University
of Chinese Medicine (Zhengzhou) in 1983 and a Master’s degree in Clinical
Pediatric Immunology from The Graduate School of China Academy of
Chinese Medical Sciences (Beijing). She was a Visiting Scientist at Stanford,
and postdoctoral fellow in Clinical Immunology at Johns Hopkins (Baltimore)
where she was appointed instructor in 1997. She Joined the Division of
Pediatric Allergy and Immunology, Pediatric Department and was promoted
to Professor of Pediatrics with tenure at the Icahn School of Medicine at
Mount Sinai in 2009. She has combined expertise in immunology and
Chinese medicine. Her research has yield over 100 publications. She has trained over fifty
residents, clinical fellows, post-doctoral fellows, graduate students, medical students, and
visiting scientists. She has chaired prominent committees about the use of alternative medicines
for allergic diseases in the US and internationally. She recently joined Department of
Microbiology and Immunology as Professor and in the process to establish a Center of
Excellence for Clinical Immunology and Integrative Medicine. She was awarded the Future of
Health Technology Award for 2016. She is co-author of Traditional Chinese Medicine, Western
Science, and the Search for a Cure for food allergy with Henry Ehrlich.
Eric Brand is a licensed Chinese medicine practitioner with a passion for materia medica and
herbal quality discernment. After graduating from the Pacific College of Oriental Medicine in
2003, Eric spent over a decade pursuing academic and clinical opportunities in Taiwan, Hong
Kong, and mainland China. He earned his PhD at the School of Chinese Medicine at Hong
Kong Baptist University with a focus on Chinese herbal pharmacy, and he serves as a TCM
advisor to the American Herbal Pharmacopoeia. Eric has written or translated a variety of
modern and classical texts and peer-reviewed articles, and he served as Chair of the U.S.
delegation on the ISO Technical Committee for international TCM standards (ISO TC 249) from
2014 to 2017.

Welcome to the “1st International Conference on the Forefront of Complementary and Integrative Medicine,” which takes place at the Joseph B. Martin Conference Center of Harvard Medical School in Boston October 29-30, 2018. Please visit the website for more details: https://www.icfcim.com

2018年10月29-30日,哈佛大学医学院Josheph B Martin Conference Center  首届中西医替代及整合医学大会  最后一周注册机会!大会由哈佛医学院和北京中医药大学主办 Journal of  Phytomedicine ,麻州中医学会协办,届时世界顶级专家教授云集,包括哈佛医学院、NIH、斯坦福大学等十位著名教授李豫伟Thomas Efferth、北中医徐安龙校长,哈佛医学院结合医学系主任,NIH补充结合医学中心主任Helene Langevin,香港浸会大学中医学院院长吕爱平,香港中文大学中医药研究所所长梁秉中,北中医东方医院副院长林谦等。聆听中西医学发展前沿,领略名家风采,机会难得!对哈佛和MIT学生、Speaker 团队成员免注册费,提供会议午餐,但免费名额有限(签到时需提供学生或工作ID),请参会人员尽快注册https://www.icfcim.com/registration.html。
1st International Conference on the Forefront of Complementary and Integrative Medicine

The deadline for priority consideration is SEPTEMBER 1, 2018.

All proposals are subject to review by session chairmen and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, a select number of conference sponsors & vendors who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Significance of traditional medicine in treating human diseases

Advantages of a multi-components and multi-targeted approach in treating complex human diseases

October 29-30, 2018

There are two major therapeutic approaches in treating human diseases. One involves the use of sophisticated molecular approach for the development of novel medicine, which target specifically at certain disease genes, receptors, or enzymes. The other involves the use of holistic approach with herbal medicine such as traditional Chinese medicine (TCM). The later trend has gain increasing popularity because Western medicine is seen either ineffective in certain chronic diseases, or produces adverse effects, or too costly. Interestingly, both Western medicine and herbal medicine share the common believe that human health is associated with functional balance. However, the Western medicine though provides fast relief of symptoms at the disease site, particularly under critical conditions, however, the single chemical entity usually targeting on single receptor site or a section of gene may not be sufficient to restore the functional balance of the entire body. On the other hand, herbal medicine with multi-components/multi-targeted approach, strives to focus on the functional balance of the body in a holistic manner. Therefore, in a broader perspective, herbal medicine should have certain advantages in dealing with human diseases especially in chronic diseases. This conference will demonstrate the scientific basis of traditional medicine in treating human diseases and case studies of preclinical and translational approaches to validate traditional medicine will be presented.

Impacts of genomic, proteomic, and metabolomics approaches in traditional medicine studies

October 29-30, 2018

The recent advancements in genomic, proteomic and metabolomics are affecting the way traditional medicine are studied. Rapid development of big data collection, management and interpretation is changing the strategies to understand traditional medicine and its impact in treating human diseases. case studies of preclinical and translational approaches to validate traditional medicine will be presented.

Scientific Program: October 29, 2018

Opening Remarks: Conference Chair: Professor David Y-W Lee, Harvard Medical School/McLean
Professor Yuanyuan Shi, Conference Executive Director, Beijing University of Chinese Medicine
Welcome Address
Dr. An-Long Xu 
President, Beijing University of Traditional Chinese Medicine
Track 1: Moderator: Professor Scott Lukas; Professor Aiping  LYU
Experimental and clinical experiences with artesunate as anticancer drug
Professor Thomas Efferth
Professor, Johannes Gutenberg University and Chief Editor of Phytomedicine
Novel mechanism of immune response regulated by APA
Professor An-Long Xu
President, Beijing University of Traditional Chinese Medicine 
Exploring the use of traditional chinese medicine, kudzu, for alcohol abuse
Professor Scott E. Lukas
Director, McLean Imaging Center
Harvard Medical School/McLean  Hospital
Coffee Break
Track 2: Moderator: Dr. Thomas Efferth
Natural Products Derived from TCM in Treating Opioid Use Disorders
Professor David Yue-Wei Lee
Director of Alternative Medicine Center
Harvard Medical School/McLean Hospital
Disease diagnosis in Western medicine and Pattern Classification in Chinese Medicine: Integration and beyond
Professor Aiping LYU
Dean and Chair Professor in Chinese Medicine, Hong Kong Baptist University
Group Photo and Lunch
Track 3: Moderator: Dr. Thomas Efferth
Development of Traditional Medicines to Botanical Drugs in the U.S.
Dr. Charles Wu
Botanical Review Team.
Office of Pharmaceutical Quality, CDER, FDA.
       Translating molecular mechanisms into useful therapeutics of Alzheimer’s disease
Professor Can (Martin) Zhang 
Harvard Medical School
Treatment of Septic Shock using an Intergrative Medicine Approach
Professor Jianxun Wang
Beijing University of Chinese Medicine
Fatigue, microbiome and TCM tongue diagnosis. - 216 clinical case analysis
Dr. Jing Liu, M.D., Ph.D.
Integra Wellness Health, Massachusetts Chinese Medicine Association
The Study on the Effective Mechanism of Acupuncture Treating on Post-stroke Aphasia
Prof. Jingling Chang
Dong Zhi Men Hospital Affiliated to Beijing University of Chinese Medicine
Coffee Break
Track 4: Moderator: Dr. Yuanyuan Shi
Cold-Induced Lipokines in Thermogenesis and Metabolism
Professor Yu-Hua Tseng
Joslin Diabetic CTR, Harvard Medical School
Treating Chronic Heart Failure - A perspective from a combined approach of TCM and Western Medicine
Professor Qian Lin, M.D., Ph.D.
Vice-president, Dongfang Hospital
Acupuncture in chronic pain management
Professor Lucy Chen
Harvard Medical School
MGH center for Pain Medicine  
Panel   Discussion: Dr. Tao Lu
Reception Dinner Presentation by President An-Long  Xu / David YW Lee

Scientific Program: October 30, 2018

Track 5: Moderator: Dr. Leung Ping Chung
Cancer Prevention and Therapy through Natural Products
Professor Dean W. Felsher
Professor of Medicine-Oncology and PathologyStanford University
Extracellular Hsp90 and the tumor microenvironment
Professor Jay Daniel
Dean at Sackler School of Graduate Biomedical SciencesTufts University 
Acupuncture, connective tissue and peripheral sensory modulation
Professor Helene M Langevin, M.D., C.M.
Bernard Osher Professor in Residence of Complementary and Integrative Medical Therapies Institution, Brigham and Women’s Hospital
Identification of separate circuits driving affective pain versus reflexive-defensive reactions—implication on pain measurement in animals
Professor Qiufu Ma
Neurobiology, Harvard Medical School
Coffee Break
Track 6: Moderator: Dr. Jian Kong
Skin resident T cells in human health and disease
Professor Rachael A. Clark, M.D., Ph.D.
Immunology, Harvard Medical School
Enhancing clinical practice with Medicinal Supplements through evidence-based research
Professor LEUNG Ping Chung
The Chinese University of Hong Kong
Track 7: Moderator: Dr. John Qunhao Zhang Dr. Zhi-Ping Li
13:15 -13:45
Holistic Approach to Quality Control of Traditional Chinese Medicines
Professor De-An Guo
Shanghai Research Center for TCM Modernization
Evaluation of Herb Blend Extracts (HBE) on Anti-Anxiety, Anti-Depression and Hypnosis Effect in Mice Studies
Dr. Zimin Liu
 Senior Research Scientist,  California Nutritionals LLC
Tanshinones and their synergistic combination for prostate cancer therapy
Professor Jin-Rong Zhou
Harvard Medical School, Beth Israel Deaconess
Brain imaging study of the non-specific effect in acupuncture treatment
Professor Jian Kong
Harvard Medical School, CTR for Acupuncture Neuroimaing
Coffee Break
Track 8: Moderator: Dr. John Qunhao Zhang Dr. Zhi-Ping Li
Molecular Imaging of Disease Processes and Therapy
Professor Howard Chen
Tufts University
The functional genes in licorice
Professor Ying Liu
Beijing University of Chinese Medicine
Miliusanes As Novel Antitumor Agents Identified from Miliusa Plants
Professor Hongjie Zhang
Hong Kong Baptist University
Conference Adjourn

For more details on the conference, please contact:

Dr. Yuanyuan Shi
Executive Director, Conferences
Beijing University of Chinese Medicine
Email: yshi@bucm.edu.cn
Dr. David Y.W. Lee
Scientific Program committee, Chair
Harvard Medical School/McLean Hospital
Email: dlee@mclean.harvard.edu
Dr. Thomas Efferth
Scientific Program committee, Co-Chair
Chief Editor
Email: efferth@uni-mainz.de
Dr. Lu Tao
Scientific Program committee, Co-Chair
Beijing university of Chinese Medicine
Email: taolu@bucm.edu.cn
Can (Martin) Zhang, M.D.,Ph.D.1
Jin-Rong Zhou, PhD
Yu-Hua Tseng, Ph.D.
Hongjie Zhang, Ph.D., Professor
是否覺得,在一腳踏入職場之後,除了專業技能之外,似乎還有許多因素,影響著我們在職場上成功與否?身為亞洲人,是否不那麼了解,如何在美國企業文化下發光發熱?BTBA將邀請Judy Shen-Filerman 提供專業職涯諮商講座。與大家分享亞裔專業人士,如何在美國企業文化的大環境下培養獲得賞識與升遷的機會!

1:30-2:00 pm: 報到
2:00-3:30 pm: 講座
3:30-4:30 pm: Networking

關於Judy Shen-Filerman (https://goo.gl/bxzY8N)

Do you know what factors are important other than professional skills to help you thrive in your career? As an Asian, have you puzzled why hard work doesn’t always lead to career success in a US corporate world? Come to this BTBA workshop presented by Judy Shen-Filerman, a professional career coach, who will tell you the critical factors for recognition and promotion in the US organization!

1:30-2:00 pm: Registration
2:00-3:30 pm: Workshop
3:30-4:30 pm: Networking

Registration info: https://goo.gl/isT512
About the speaker Judy Shen-Filerman (https://goo.gl/bxzY8N)

Saturday, September 8th
1:00 - 5:00 p.m. (EST)
Harvard School of Public Health 
Kresge G1
On-Site Judging Teams
Jessica Alderman Zeaske, Ph.D., MBA
Director, Healthcare Investments, GE Ventures
SU Lingyun
Director, Alibaba Health Research Institute
Senior VP at Porton;
Founder and Director, Beijing Bodun Chongde Charity Investments; Founder and Director of Network Think Tank;
Vice President, Moganshan Research Institute Expert Advisory Committee;
Vice Chairman, China Digital Assets Research Institute;
Director, United States Hope Investment Fund
Jing Ma, MD, PhD
Co-founder and Board Member, President, U.S.-China Health Summit; Director of China Center,
Associate Professor, Department of Population Medicine, Harvard Medical School
Kate (Xiaokui) Zhang
Senior Director, Global Bio-Therapeutic, Sanofi 
Shaan Gandhi, MD, MBA
Principal , Longwood Fund
Olivia Ho. Cheng
Board Member, U.S.-China Health Summit; CEO, Aurora Healthcare Corp.
Grannum R Sant, MD, FRCS, FACS
Professor and Former Chair of Urology and Urology Residency Program Director, Tufts University School of Medicine
Partner, Lodestone Capital Partners
YANG Hailing
Senior Analyst, Decision Resources Group
Register to connect with judge panel right now!
More information? please visit: https://www.uschinahealthsummit.org/innovation
Any questions? Reach us at info@uschinahealthsummit.org
各位会员:好消息。著名医学气功专家北京中医药大学博导刘天君教授将于9/30/2018周日莅临哈佛中医药论坛授课!本次讲课包括现场带领大家练习。名额有限,先来先得。欢迎大家参加!请提前报名!谢谢!John Zhang



美国马萨诸塞州伍斯特市,中国上海,2018611——全球领先的开放式生物技术平台公司药明生物(WuXi Biologics, 2269.HK)今日宣布,公司计划投资6,000万美元(约合3.8亿人民币)在美国马萨诸塞州伍斯特市(隶属波士顿大都会区)新建现代化生物制药临床样品和商业化生产基地,并创造约150个工作岗位。




“马萨诸塞州拥有技术领先的公司、顶尖的学术机构和充满竞争力的人才,已经形成全球最具活力的生命科学创新生态系统之一。”马萨诸塞州州长查理·贝克(Charlie Baker)先生说,“我们很高兴药明生物选择在马萨诸塞州进行战略布局,更多企业的投资和快速发展将共同构建更加完整的创新生态系统。”

“这几天在伍斯特市与药明生物管理层的会见交流,让我深信他们将对这里的生命科学产业做出巨大贡献。”马萨诸塞州副州长卡琳·波利托(Karyn Polito)女士表示,“我们很高兴为伍斯特市生物医药产业园的发展而努力,我们将继续为各个领域的合作伙伴提供支持。”

“伍斯特市正在打造全新的生物医药产业园区,我们热烈欢迎药明生物成为首家选择入驻于此的企业。”伍斯特市政执政官Edward M. Augustus, Jr.先生表示,“作为全球生物医药市场中地位日益攀升的投资目的地,伍斯特市十分期待新园区的正式开幕,同时帮助药明生物的首个美国生产基地顺利落成。”

“我们很高兴药明生物选择了美国马萨诸塞州,更重要的是选择了伍斯特市。在马萨诸塞州贝克-波利托政府和伍斯特市政府的支持下,我们通过巨大努力最终促成了此项目成功落地。对伍斯特市而言,今天又是一个重要的日子。”伍斯特商业发展局总裁兼首席执行官Craig L. Blais先生表示。

麻省生命科学中心(MLSC)总裁兼首席执行官特拉维斯·麦克瑞迪(Travis McCready)先生表示,“我们很高兴见证药明生物在美国伍斯特市布局生产基地这一重大里程碑。药明生物全球领先的生物制药专业技术和能力将进一步巩固这里的生命科学创新生态系统,帮助马萨诸塞州的生物制药公司更迅速高效地开发创新疗法。我们将继续为此项目的顺利完成而努力。”






WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
– WuXi Biologics’ first overseas site in the United States
WORCESTER, MA and SHANGHAI, June 11, 2018 – WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
This state-of-the-art “facility of the future” will be built upon the novel approach that WuXi Biologics has pioneered in deploying single-use bioreactors. It is also designed to run continuous bioprocessing, a next-generation manufacturing technology to be implemented in America for the first time. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.
The new manufacturing facility supported by the Government of Massachusetts, the Worcester Business Development Corporation (WBDC) and the Massachusetts Life Sciences Center (MLSC), is the Company’s first overseas site in the United States, as well as the third outside China subsequent to Ireland and Singapore new sites.
“Massachusetts is home to one of the world’s most dynamic life sciences ecosystems, with leading companies, top-tier academic institutions, and a globally-competitive workforce,” said Massachusetts Governor Charlie Baker. “We are enriched when companies grow and invest here and are pleased to welcome WuXi Biologics’ expansion.”
“Having met WuXi Biologics’ leaders during their recent trip to Worcester, I am confident that they will contribute greatly to the city’s life sciences industry,” said Ms. Karyn Polito, Lieutenant Governor of Massachusetts. “I have been pleased to work on the development of Worcester Biomanufacturing Park and our Administration remains committed to supporting our public private partnership.”
“The City of Worcester is thrilled to welcome WuXi Biologics as its first tenant to the new Biomanufacturing Park,” said Worcester City Manager, Edward M. Augustus Jr.. “As a growing destination in the global biomedical market, the city looks forward to officially opening this impressive campus and is eager to host WuXi Biologics in their first US manufacturing facility.”
“We are delighted that WuXi Biologics has chosen the United States, Massachusetts, but most importantly Worcester. We competed very hard for this one and we prevailed. The Baker / Polito Administration and the City of Worcester stepped up to make this possible. Another great day for Worcester,” said Mr. Craig L. Blais, President and CEO of WBDC.
“We are excited to reach this important milestone on developing WuXi Biologics’ first US bio-manufacturing facility and to announce their intention to move to Worcester,” said Mr. Travis McCready, President and CEO of MLSC. “WuXi Biologics brings a global biologics manufacturing expertise that will enhance our life sciences ecosystem and help Massachusetts biopharma companies develop novel therapies quickly and efficiently. We look forward to continuing to work to finalize this project.”
“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. We believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.
Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. Many partners of WuXi Biologics are located within two hours of this new site. We are all very excited to initiate our first US site to enable local companies and expedite biologics development in the United States. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

药明康德领投Insilico Medicine战略融资,用人工智能加速新药研发

药明康德 药明康德 Yesterday

药明康德领投Insilico Medicine战略融资,利用新一代人工智能加速新药研发

该战略融资由药明康德风险投资基金领投,蘭亭投资(淡马锡控股子公司)、BOLD Capital和Juvenescence跟投。

马里兰州巴尔的摩市和中国上海2018年6月11日电 /美通社/ -- 2018年6月11日,美国新一代人工智能公司Insilico Medicine宣布完成由药明康德风险投资基金领投的新一轮战略融资。Insilico Medicine总部位于马里兰州巴尔的摩市,专注于将深度学习等新一代人工智能技术应用于靶点识别、药物发现以及抗衰老研究。本轮战略投资建立在Insilico Medicine基于生成对抗网络(Generative Adversarial Networks, “GAN”)和强化学习(Reinforcement Learning, “RL”)等人工智能技术开发的药物发现流程成功获得实验验证的基础上,并旨在将Insilico Medicine的先进的人工智能技术与药明康德强大的实验能力紧密结合。

本轮融资由药明康德风险投资基金领投,其它投资人包括淡马锡控股旗下的蘭亭投资,和由Peter Diamandis创立的主要投资快速成长型高科技公司的BOLD Capital。作为Insilico Medicine在药物发现领域的合作伙伴,专注于开发延长寿命技术的Juvenescence也参与了此次投资。

Insilico Medicine创始人兼首席执行官Alex Zhavoronkov博士说:“药明康德是全球领先的药物和医疗器械研发开放式能力和技术平台公司,拥有大批专注于解决制药领域最复杂问题的顶尖合成和药物化学家及生物学家。我们很荣幸能够与药明康德以及其他在药物发现和人工智能领域拥有深厚专业知识的国际知名投资者合作。”

这笔投资旨在支持Insilico Medicine采用新一代机器学习技术研发新的药物候选分子,并进一步增强该公司发现生物标志物的能力。

药明康德董事长兼首席执行官李革博士评论说:“我们与Insilico Medicine拥有共同的愿景,都相信人工智能和机器学习将提高临床前实验的成功率并优化新药研发的流程。我们对Insilico Medicine的新一代人工智能技术印象深刻,并将与之密切合作,结合药明康德强大的研究能力将这一技术提升到一个新的水平,从而更好地为制药行业赋能,服务。”


药明康德首席财务官兼首席投资官胡正国先生表示:“对Insilico Medicine的战略投资将我们的合作伙伴关系带入到新的层次,通过将我们自身的研发能力和Insilico Medicine的AI技术更紧密地整合,我们可以更好地服务整个生物制药行业。我们一直在寻求能加速药物研发过程的人工智能技术。Insilico Medicine最吸引我们的是他们的技术能力及其应用的广度,包含从使用新一代人工智能技术进行靶点鉴定和小分子生成,到区块链技术和抗衰老研究等领域。”

药明康德(603259, SH)是一家国际领先的开放式能力与技术平台公司,为全球制药、生物技术以及医疗器械等领域提供从药物发现、开发到市场化的全方位一体化的实验室研发和生产服务。本着以研究为首任,以客户为中心的宗旨,药明康德通过高性价比、高效率的服务平台帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗器械测试等,正承载着来自全球30多个国家的近3000多家创新合作伙伴的数千个研发创新项目,致力于将最新和最好的医药和健康产品带给全球病患,实现“让天下没有难做的药,难治的病”的梦想。


BOLD Capital Partners简介
BOLD Capital Partners (“BOLD”) 是一家风险投资公司,主要投资目标为早期阶段和成长型科技公司。 BOLD对能够利用颠覆性技术来改造世界并为人类社会中存在的巨大挑战提供创新性解决方案的企业特别感兴趣。该投资平台利用Singularity University和Peter Diamandis ecosystem 来积极寻求并支持世界级企业家。BOLD在加利福尼亚州圣莫尼卡和帕洛阿尔托均设有办事处。

Juvenescence有限公司是一家专注于延长人类寿命的生物技术公司。它由Jim Mellon、Greg Bailey博士、Declan Doogan博士、Anthony Chow和Alexander Pickett于2017年创立。 Juvenescence的团队由经验丰富的药物开发人员,以及众多在生命科学和药物开发方面有着成功经验的企业家组成。Juvenescence专注于开发衰老以及年龄相关疾病的疗法。


Insilico Medicine 公司简介
Insilico Medicine是一家新兴人工智能公司,总部位于美国马里兰州巴尔的摩市约翰霍普金斯大学东校园内的新兴技术中心,现于比利时、俄罗斯、英国、台湾和韩国等地均设有研发中心。公司旨在延长人类有效寿命并希望借助他们在生物标志物发现、药物开发、药物数字化以及老龄化研究上的先进技术来优化药物研发的每一个步骤。

Insilico Medicine在全球率先运用生成对抗网路(GAN)和强化学习(RL)来开发新的药物分子,这项技术可同时运用于已知靶点的疾病以及未知靶点的疾病。除了与大公司合作开发药物之外,Insilico Medicine也同时在内部开展药物发现项目,专注于癌症、皮肤疾病、纤维化、帕金森病、阿尔兹海默病、渐冻症,糖尿病、肌肉减少症和衰老的新药开发。通过与LifeExtension.com的合作,并借助于自身先进的生物信息技术和深度学习技术,Insilico Medicine开发了一系列自然保健药物。此外,Insilico Medicine还研发了消费者脸部识别应用,比如Young.AI.。
该公司2017年被NVIDIA列为全球前五大对未来人类最具影响力的公司之一,2018年更被美国知名创投研究机构CB Insights誉为2018 全球AI人工智慧百强公司。

20th SAPA-NE Annual Conference, Cambridge, MA, 

Jun 2-3

Please Join Us to Discuss 
How Can We Save the Lives of
Patients, Our Family Members,
Our Neighbors, and Ourselves.

June 2nd
8AM – 6PM
Annual Conference
Tang Center, MIT
June 2nd
6PM – 9:30PM
20th-Anniversary Banquet
Boston Marriott Cambridge
June 3rd
9AM - 3 PM
Investment Forum
Boston Marriott Cambridge

Helping Patients with Unmet Needs Through Innovation and Collaboration
June 2nd, 2018
8:00 AM – 6:00 PM
MIT, E51, Tang Center, Wong Auditorium
2 Amherst St, Cambridge, MA
Registration and Breakfast
Session 1: 
Patients with Unmet Needs Require New Treatment and Healthcare Innovation
Lunch and Exhibition
Session 2: 
Transformative Innovation Demands Novel Platforms
Coffee Break and Exhibition
Panel Forum:
Collaborations and Opportunities Across the Ocean
Session 3: 
Global Collaboration Drives Biomedical Innovation and Productivity
Closing Remark and Networking

SAPA-NE 20th Anniversary Celebration Banquet
(Biocytogen Night)
6:30 PM – 9:30 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
Welcome Remarks
Keynote Speech and Award
Dinner / Celebration

Investment Forum
June 3rd, 2018
9:00 AM – 3:00 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
Opening Remark
Keynote Talks
Panel Discussion
Roadshow Presentation

Invited Speakers
George M. Church, Ph.D.
at Harvard & MIT
Dost Öngür, M.D.
Chief of the Psychotic Disorders Division, McLean Hospital
Shidong Jia, Ph.D.
Founder & CEO, Predicine Holdings Ltd.
Chris Garabedian
Chairman and CEO, Xontogeny
WilliamL. Fodor, Ph.D.
Acting CSO Biostage, Inc. 
Director Translational Sciences, Cell Therapy Group
Morris J. Birnbaum, M.D., Ph.D. 
SVP and CSO, Internal Medicine Research, Pfizer Inc.
Steve Yang, Ph.D.
EVP, CBO & CSO, WuXi AppTec
Yuelei Shen, Ph.D.
President and CEO,  Biocytogen Co Ltd.
Shenghong Steve Yang, Ph.D.
Manager, Sales and BD at Sino Biological US Inc.
Hong Cheng, Ph.D. & MBA  
Associate Vice President, Head of Research Strategy and Effectiveness for Global Research at Sanofi
Jin Li, Ph.D.
Chairman and CEO, HitGen
Yulian Zhang, Ph.D., MBA 
Executive Director, Kelun-Biotech Pharmaceuticals
Bill Liang, Ph.D.
CEO, CF PharmTech, Inc.
史文钊, Ph.D.
Libing Yu, Ph.D.
Sr. Vice President, Business Development, Viva Biotech
Wenseng Wendy Pan, J.D. & Ph.D.
Partner, Sidley Austin LLP.

Ken Li, Ph.D.
Managing Partner, Yuanming Capital
Scott Zheng, MBA
Partner & CEO, SunForest Captital
Brad Loncar
CEO, Loncar Investments


You are warmly welcome to join our "20th SAPA-NE Annual Conference and 20th Anniversary Celebration" at MIT/Marriott Cambridge on Sat-Sun 6/2-6/3/2018 (www.SAPA-NEweb.org) 
The theme of 20th SAPA-NE Annual Conference (Sino-American Pharmaceutical Professionals Association - New England)  is “Helping Patients with Unmet Needs through Innovation and Collaboration”. Please join us to learn and to discuss this important topic in our lives with Big Pharmaceutical Executives, Star-up Biotech Entrepreneurs, Well-known University Professors, Famous Physicians, and International Investors. We are confident that you would not only learn frontier science, grasp the latest Drug R&D trend, understand updated medical advancement, but also find the conference as a unique opportunity expand your professional network in particular with pharmaceutical/biotech and Health Care industry with Chinese origin. Hope everyone also enjoy the memorable SAPA-NE 20th Anniversary.
The Annual Conference comprises a full-day program on 6/2 Sat 9am-6pm at MIT Tang Center, Wong Auditorium at 2 Amherst St, Cambridge, MA, followed by a SAPA-NE 20th Anniversary Banquet 6:30-9:30pm at Boston Marriott Cambridge, 50 Broadway, Cambridge, MA. In addition, we will have a Biotech/HealthCare Investment Event and Special Activities at Boston Marriott Cambridge on 6/3/2018 Sunday 9am-3pm.
欢迎来波士顿参加20届新英格兰美中药协年会和20周年庆典, MIT and Marriott Cambridge, 6/2-6/3/2018. 制药公司总监,生物制药创业家, 知名学术权威,著名医学专家, 和投资巨鳄和大家一起探讨<通过创新和合作来帮助危难中的病人><Helping Patients with Unmet Needs through Innovation and Collaboration>
Registration at http://sapa-neweb.org/AC2018.php
Annual Conf Admission for both 6/2 9am-6pm and 6/3 9am-3pm, 
$25 early bird by 5/10; $30 regular by 5/25; $40 on site after 5/26
SAPA-NE 20th Anniversary Banquet, 6/2 6:30-9:30pm
$50 with limited capacity by 5/25; $60 on site after 5/26

Best regards,
20th SAPA-NE Annual Conference Organizing Committee

Taiwan Bio Forum: Healthcare Innovation Beyond Borders
Date:  Sunday, June 3rd
Venue:  Joseph B. Martin Conference Center (Harvard Medical School) 
In the advent of the International BIO Convention in Boston, join us for a day of healthcare and biomedical innovations at Taiwan Bio Forum, jointly hosted by MJNE and DCB on June 3rd at the Joseph B. Martin Conference Center at Harvard Medical School. Meet and network with top leaders in biopharma, medtech, venture capital, and academia from Taiwan and around the world.
This event will feature more than 20 speakers from Sanofi Genzyme, Samsung VenturesLEO PharmaSR One, M Ventures, MPM CapitalF-Prime CapitalArtiman VenturesMIT Alumni AngelsMilitia Hill Ventures, and Johnson & Johnson Innovation. The audience will also hear from keynote speakers Michael LaRhette, President, MassChallenge and Kate Merton, Head of JLABS at NYC & Boston, Johnson & Johnson Innovation.
Click photos for Speaker’s Bio
Herbert Wu
Fong-Chin Su
Deputy Minister
Ministry of Science and Technology
Michael LaRhette
Chen-Yang Shen
Chief Executive
Taiwan Biobank
David Lucchino
Johnsee Lee
Taiwan Biotech Industry Organization
Shaoyu Chang
Investment Manager
VI Ventures
Kate Merton
Head of JLABS
Johnson & Johnson Innovation
Fulung Ko
Chief Administrative Officer
Taipei Exchange
Joan Lau
Managing Partner
Militia Hill Ventures
Akhil Saklecha
General Partner
Artiman Ventures
Greg Sieczkiewicz
Chief IP Counsel
MPM Capital
Kevin Chu
F-Prime Capital
Christopher Kim
Managing Partner
Novatio Ventures
Patrick DeCourcy
Principal Program Manager
Sanofi Genzyme
Vikas Goyal
SR One
Hyuk-Jeen Suh
Head of Investment
Samsung Ventures
Michael Sierra
Vice President
LEO Sci. & Tech
Daniel Franke
M Ventures
Jeng-Shin Lee
Chief Scientific Officer
AB Biosciences
Mary Ann Picard
Dir. of Operation
Patrick Rivelli
Savran Technologies
Ying K. Tam
Managing Dir. of Health
MaRS Ventures
Joel Berniac
CEO and Co-Founder
Akrivis Technologies
Technology Showcase:
Company Name
Brief Company Introduction
ACT Genomics
​ACT Genomics is a leading CAP-accredited cancer molecular information service provider, with proprietary NGS-panels and chip-based platform, coupling with integrated medical informatics pipeline, we transform cancer treatment paradigm and support biopharma in biomarker exploration and companion diagnostic development.
Tsung-Kai Wu
Sr. Associate Director, Business Development
Mao Ying Genetech Inc. ​
Mao Ying Genetech Inc. is a bioinformatics data analytic company dedicated to providing algorithmic technologies for diagnosis and therapy of cancer.  At Mao Ying, a multi-disciplinary team – comprising medical and computer scientists as well as a marketing expert – works together to develop diagnostic biomarkers for various types of cancer.  By applying the novel Gene Expression Portrait, we have successfully identified gene markers with potential applications to diagnosis or therapy, and developed several clinically validated products in this line, including OncoDx and MetaDx for cancer diagnosis and OrganID for human organ identification.
Pei-Ing Hwang​
General Manager
ASUS Life Corporation
ASUS Life focus on the development of smart medical application. With HealthCloud and AI application as the infrastructure, ASUS Life has PhenoFinder as a distributed database for medical data, OmniCare as a medical IoT platform, and AiNurse as a virtual application in telecare, to help hospitals develop the precision medicine.
Jerry Hsu
Senior Manager
Our mission is to create patient’s virtual avatar for better visualization to serve clinical and educational needs. Through Virtual Reality, our applications allow doctors to see through patient’s body for better surgical planning or radiotherapy simulation. In the student or patient education, the interactive and immersive learning experience enables users to eliminate conceptual hurdle so they can better understand human body. In Augmented Intelligence, our goal is to advance medical intelligence through simulated visualization.
Sam Jang
Funique VR
​Funique dedicated into realizing Stereoscopic 3D VR in film industry, and creating new generation platform for viewers.
Our Medical Stereo VR System - Observing Surgeries through Stereo VR Documenting all kinds of surgeries with Funique’s 8K per eye VR solution. Combining simulation and real-time footages, it solve the problems of lack of resources. And let medical students around the world have the chance to observe some of the greatest surgeons on earth.
Chien-Hsiang Chao
Project Manager
Bio Preventive Medicine Corp.
Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company, focusing on developing novel biomarker-based diagnostics for chronic diseases and oncology. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD), which has been applied to evaluate renal effect in a phase IIIb global clinical trial, MARLINA-T2D™, sponsored by Boehringer Ingelheim. We can help in the development of drugs not only in evaluating renal efficacy but also renal safety. BPM welcomes strategic partnerships in expanding the product pipeline and technology platform for biomarker detection, as well as international partnership for commercialization.
Dave Lee
LumiSTAR Biotechnology, Inc.
LumiSTAR Biotechnology is an expert in iPSC technology, optogenetic tools and functional indicators. There are two main applications of our technique: (1) All-optical platform incorporated with AI and machine learning for phenotypic screening, drug discovery, and toxicity testing. (2) Organs-on-chips for precision/personalized medicine.
Yu-Fen Chang, Ph.D
GenomeFrontier Therapeutics, Inc.
​​CAR-T cell therapy is a gene therapy in which patients’ white blood cells are genetically engineered to fight their own cancer.  Achieving more than 90% remission rate in patients with advanced blood cancers, this innovative immunotherapy offers new hope to dying children and adults with advanced blood cancers.  Though powerful in treating advanced blood cancers, conventional CAR-T is futile in fighting solid tumors due to the drawbacks and limitation imposed by the viral vectors used in CAR-T cell engineering.  GenomeFrontier is poised to change the outlook for patients with otherwise incurable advanced solid cancers by confronting this very challenge with bold solutions using our core technologies including Quantum pBAc, a revolutionized non-viral genetic system capable of loading 30 times more genes than the viral method and an innovative cell culture system designed for expending engineered CAR-T cells to a therapeutic quantity while maintaining its potency.  With these revolutionary technologies, we are developing universal super CAR-T therapies for solid cancers which are virus-free, reversible, and potent enough for treating a wide-range of cancers in a much safer fashion than the conventional CAR-T therapies.
​Chiung-Yuan Wu
Elixiron Immunotherapeutics Inc.
Elixiron Immunotherapeutics Inc. is a pre-clinical stage company focused on the development of transforming immunotherapy to treat chronic hepatitis B and cancer.  Our lead product EI001 is a fully human monoclonal antibody ready for IND-enabling studies as a potentially first-in-class curative HBV immunotherapy.  For cancer immunotherapy, we are developing therapeutic antibodies targeting tumor microenvironment to reactivate anti-tumor immunity and block cancer metastasis. Elixiron is positioned to launch our first clinical trial and deliver one additional drug candidate for clinical development in 18 months.
Hung-Kai Chen, M.D., Ph.D.
Meeting Agenda:

Registration & Breakfast
Welcome Remarks:
‧Herbert Wu, PhD, President, Development Center for Biotechnology
‧Crystal Sung, PhD, President, Monte Jade New England
Opening Remarks by Guest of Honor:
‧Deputy Minister Fong-Chin Su, PhD, Chief Executive Officer, Taiwan Biomedical Development Board
Keynote: Powering the Future of Healthcare by Empowering Global Entrepreneurs
‧Michael LaRhette, President, MassChallenge
Taiwan Biobank for the Health of Future Generations
‧Chen-Yang Shen, PhD, Chief Executive Officer, Taiwan Biobank
Coffee Break
Startup Ecosystem Panel Discussion – “Fostering Entrepreneurship and Innovation”
‧Moderator: Herbert Wu, Development Center for Biotechnology
‧David Lucchino, Chairman of Massachusetts Biotechnology Council
‧Johnsee Lee, Chairman, Taiwan Bio Industry Organization
Technology Showcase: Precision Medicine & Digital Health
‧ACT Genomics, Mao Ying Genetech, ASUS Life Corporation, Augmented Intelligence, Funique VR Studio, Bio Preventive Medicine, Lumistar Biotechnology, GenomeFrontier Biosciences, Elixiron Immunotherapeutics
Welcome Remark:
‧Shaoyu Chang, Investment Manager, VI Ventures
Keynote: JJI & JLABS – Partnering Globally in Healthcare Innovation
‧Kate Merton, PhD, Head of JLABS at NYC & Boston - Johnson & Johnson Innovation
The Advantages of Taiwan's Capital Market
‧Fulung Ko, Chief Administrative Officer, Taipei Exchange (TPEx)
VC Panel Discussion - "Building Cross-Border Partnerships"
‧Moderator: Joan Lau, Managing Partner, Militia Hill Ventures
‧Akhil Saklecha, General Partner, Artiman Ventures
‧Greg Sieczkiewicz, Managing Director, Chief IP Counsel, MPM Capital
‧Christopher Kim, Managing Partner, Novatio Ventures
‧Kevin Chu, Associate, F-Prime Capital Partners
Corporate Panel Discussion - "Cross-Sector Innovations in Healthcare"
‧Moderator: Patrick DeCourcy, Principal Program Manager, Global Medical Affairs, Immunology, Sanofi Genzyme
‧Vikas Goyal, Associate, SR One
‧Hyuk-Jeen Suh, Head of Samsung Ventures East Coast
‧Michael Sierra, Vice President, LEO Science & Tech Hub
‧Alicia Irurzun Lafitte, Principal, M Ventures
Academia-Industry Panel Discussion - "Fostering a Robust Ecosystem"
‧Moderator: Jeng-Shin Lee, Chief Scientific Officer at AB Biosciences
‧Mary Ann Picard, Director of Operations, M2D2 @ UMass
‧Patrick Rivelli, Director of Life Sciences Track, MIT Alumni Angels
‧Ying Tam, Head of Healthcare, MaRS Ventures
‧Joel Berniac, President, CEO and Co-Founder, Akrivis Technologies
Closing Remarks
‧Leon Chen, Vice President, Monte Jade New England
Title: US-Taiwan Night 2018: AI in Healthcare 
Date & Time: 5:30 pm - 9 pm, June 6th
Venue: Boston Marriott Cambridge
Registration:  https://twbionight.eventbrite.com/

Dear CABA Members and Friends,

We cordially invite you to attend at the upcoming CABA/CBA 2018 Biopharma Forum – “Simcere Night”. The event will be held at Harvard Medical School’s Joseph B. Martin Conference Center (77 Avenue Louis Pasteur, Boston, MA 02115) from 5:30 PM to 8:30 PM on Tuesday, June 5, 2018.

As non-profit organizations based in Boston and Washington DC, respectively, Chinese-American BioMedical Association (CABA) and China Biopharmaceutical Association (CBA) strive to facilitate the communication of the latest advances in biomedical research and development; to assist in the exploration of new biotech/pharmaceutical market opportunities in the US and China; and to promote member career development and community service. Since inception, CABA and CBA have evolved into some of the most active and engaging Chinese American professional organizations locally in the greater Boston and DC Area, nationwide in the US and overseas in China.

For the upcoming 2018 Biopharma Forum, we expect to have 100+ prominent executives, investors, scientists, officials from biopharmaceutical companies, leading research institutions, venture capital investors, entrepreneurs and regulatory agencies from both US and China to come together to discuss the current state and future trend of the life science industry.

美中生物醫藥協會第11屆年會暨波士頓生物醫藥論壇 5/19

🏨Boston Marriott Newton
📍2345 Commonwealth Ave, Newton, MA 02466
🕙8:00 AM to 9:00 PM on Saturday, May 19, 2018.


Bill Fodor, PhD
Chief Scientific Officer

Felix Hsu, MBA
Head of WuXi Advanced Therapies

Geoff Mckay

Birgit Schultes, PhD
VP of Immunology
 Intellia Therapeutics Inc 

Yide Alan Jiang, PhD
Chief Strategic Officer
Xtalpi Inc.

Xiaole Shirley Liu, PhD
Professor of Statistics, Biostatistics, and Computational Biology
Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health

Tong-Tong Xue, PhD
CEO of Kelun Bo-Tai Biological Company
Vice President of Kelun Pharmaceutical Research Institute

Cheryl Cui, PhD
Partner, Nest.Bio Ventures
 Venture Partner, Venture Health

Sean Fu, PhD
Vice President of Luye Global R&D
President of Luye Boston R&D LLC  

Debra Yu, MD
Managing Director, Head of Cross-Border Healthcare Investment Banking
China Renaissance

Johnson Zhang, MBA
Vice President & General Manager, Perkin Elmer APAC

John Xu, PhD, MBA
Sr Vice President of Strategic Alliance

哈佛医学院华人专家学者联合会(HMS-CSSA)经历十载春秋,已经成为哈佛医学院专家学者不可或缺的交流平台之一。一年一度的哈佛华人生物医学年会(以下简称“年会”)更是HMS-CSSA每年的重头戏。2018年5月5日,年会如期在在哈佛医学院波士顿儿童医院Folkman Auditorium举办。本次年会一共分为4个部分,内容涵盖了Development and Epigenetics(发育和表观遗传学)、Signaling Pathway(信号通路)、Cancer Biology(肿瘤生物学)和 Deciphering Protein Structure and Genome Sequence(蛋白结构解析和基因组测序),堪称是一场学术盛宴。现场的火爆程度不用赘述,单从报名满额的速度就能一瞥虚实。知识的力量是无限的,但交流的机会是有限的,为了不让赶不到会场的朋友们留下遗憾,协会还特意设立了分会场和网络直播,让知识能够更好的分享给大家。
晨光初起,协会成员和志愿者们就陆续忙碌起来,准备迎接广大学者的到来。与会者一个个入场,时钟也一步步走向开幕。在HMS-CSSA会长杨淞博士简单的致辞之后,哈佛医学院院长 George Daley 教授代表哈佛医学院向广大学者致以问候。他强调了科学对于人类健康的重大贡献,也重点强调了科学工作者们间交流和紧密合作的重要性,以及科学工作者的社会责任。
开场致辞之后,哈佛医学院院长George Daley在第一个主题报告中,介绍了他带领的课题组攻克了20年来造血干细胞体外再生的难题,成功通过过表达7个转录因子将人工诱导干细胞重编程为造血干细胞的过程。该造血干细胞可以在体内自我更新并分化为红细胞和白细胞等各种血液细胞,为需要骨髓移植的患者带来了希望。
哈佛医学院院长George Daley精彩演讲
来自Whitehead研究所的美国科学院院士Rudolf Jaenisch教授首先介绍了他们实验室开发的甲基化报告系统,通过该系统可以在单细胞的水平下通过荧光衡量某一个基因启动子区的甲基化水平。接下来,他向我们介绍了使用改造后的CRISPR系统修改FMR1基因甲基化水平的工作,该工作为治疗脆性X染色体综合症提供了新的方向。
美国科学院院士Rudolf Jaenisch教授
William Pu教授来自哈佛医学院附属波士顿儿童医院,他生动地为大家介绍了“heart-on-a-chip”,这个技术是利用工程学手段将心肌细胞固定在芯片,并且可以模拟心脏功能特点。他们组利用该工具研究了包括Barth综合症和心律失常等心脏相关疾病的致病机制并筛选了可能的治疗药物。
波士顿儿童医院 William Pu教授
赵瑾(Jean Zhao)教授阐述了她对于结合靶向药物和目前迅速崛起的免疫疗法在癌症治疗中的最新发现及独到见解。她的研究显示对细胞周期蛋白依赖性激酶CDK4/6的抑制可增强肿瘤细胞的抗原呈递,并增加肿瘤内T细胞浸润,同时减少调节性T细胞(T-regs)。她同时向我们展示了联合使用p110beta 和 PD-1抑制剂在前列腺癌中的显著抗癌效果及相关最新发现。
丹娜法伯癌症研究院赵瑾(Jean Zhao)教授和祁军教授
来自哈佛医学院附属Beth Israel Deaconess医学中心的魏文毅教授为我们介绍了S6K1的最长可变剪切体p85在癌症中的重要作用。他实验室最近发现p85作为一种癌细胞分泌蛋白,可以在细胞系和小鼠模型中促进癌细胞的生长和转移。

Beth Israel Deaconess医学中心魏文毅教授
Nathanael Gray博士分享了一种新的靶向治疗癌症的策略,通过双功能小分子借用细胞自身的泛素化降解系统,以及以此技术为基础的dTAG技术,精准的定点降解靶标蛋白,来达到癌症治疗的目的。同时他们发现使用降解技术可以有效提高药物选择性,在CDK9的降解工作中他们完美解决了CDK9和CDK家族其他蛋白的选择性问题,为靶向治疗提供了新的机会。

丹娜法伯癌症研究院Nathanael Gray教授
王家槐教授从结构生物学的视角为我们阐释了神经生长因子Netrin-1与Draxin与神经受体的相互作用机制。这两个神经生长因子分别与同一神经受体DCC相互作用会引发吸引与排斥两种不同的反应。通过对三组复合物的X射线晶体结构研究及相关的神经生物学研究,揭示了通过 DCC-Draxin-Netrin-1-DCC 搭建起的桥梁形成神经细胞接触与生长的分子机制。
最后是2018年哈佛华人生命医学优秀学术奖颁奖典礼。涌金集团特别赞助了本年度学术奖的奖金,以激励哈佛的年轻学者们。 经过激烈的竞争,十二位在哈佛工作的优秀学者获得今年的学术奖。哈佛医学院刘小乐教授和谢晓亮教授为获奖者颁发了证书与奖金,以嘉奖他们在多个生物医学领域的出色成果。
Harvard Chinese Life Science Annual Symposium 2018
May 5th, 2018
Folkman Auditorium, Enders Building, Boston Children’s Hospital320 Longwood Ave, Boston, MA 02115
Organizing Committee
Harvard Medical School - Chinese Scientists & Scholars Association(HMS-CSSA)
Song Yang, Qiong Ye, Linchang Huang, Wenqing Cai, Wei Li, Bin Li, Xiaoqing Wang, Shuxi Qiao, Hong Yue, Jingyu Peng, Yue Zhang, Xianrui Yang, Miao Liu, Chan Cao, Yiming Zhou, An Xiao, Yang Zhang, Yue Huang, Lijie Xing, Mohui Wei, Shengqing Gu, Tao Wang, Xiaofeng Li, Zhengnian Li, Hui Liu, Jiye Liu, Junlin Guo, Pingping Mao, Su Wang, Shuang Zhou, Jinmiao Chen, Songwei Duan, Yanan Qi
Organizing Committee Advisors
Jianzhu Chen, Professor, Massachusetts Institute of Technology
Chuan He, Professor, University of Chicago
Xi He, Professor, Boston Children’s Hospital, Harvard Medical School
Zhigang He, Professor, Boston Children’s Hospital, Harvard Medical School
Frank Hu, Professor, Harvard T.H.Chan School of Public Health 
Xiaole Shirley Liu, Professor, Dana-Farber Cancer Institute / Harvard T.H.Chan School of Public Health 
Hongbo Luo, Associate Professor, Harvard Medical School
William Pu, Professor, Boston Children’s Hospital, Harvard Medical School
Yang Shi, Professor, Boston Children’s Hospital, Harvard Medical School
Jiping Wang, Assistant Professor, Brigham and Women’s Hospital, Harvard Medical School
Hao Wu, Professor, Boston Children’s Hospital, Harvard Medical School
Yingzi Yang, Professor, Harvard School of Dental Medicine
Junying Yuan, Professor, Harvard Medical School
Yi Zhang, Professor, Boston Children’s Hospital, Harvard Medical School
Jean Zhao, Professor, Dana-Farber Cancer Institute, Harvard Medical School
Invited Speakers
George Daley, MD, PhDHarvard Medical School, Boston Children’s Hospital
Dr. George Q. Daley seeks to translate insights in stem cell biology into improved therapies for genetic and malignant diseases. Important research contributions from his laboratory include the creation of customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the differentiation of germ cells from embryonic stem cells (cited as a “Top Ten Breakthrough” by Science magazine in 2003), and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts (cited in the “Breakthrough of the Year” issue of Science magazine in 2008). As a graduate student working with Nobel Laureate Dr. David Baltimore, Dr. Daley demonstrated that the BCR/ABL oncogene induces chronic myeloid leukemia (CML) in a mouse model, which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley’s recent studies have clarified mechanisms of Gleevec resistance and informed novel combination chemotherapeutic regimens.
Dr. Daley received his bachelor's degree magna cum laude from Harvard University (1982), a Ph.D. in biology from MIT (1989), and the M.D. from Harvard Medical School, where he was one of twelve individuals in the school’s history to be awarded the degree summa cum laude (1991). He served as Chief Resident in Internal Medicine at the Massachusetts General Hospital (94-95) and is currently a staff physician in Hematology/Oncology at the Children's Hospital and the Dana Farber Cancer Institute, and a member of the Hematology Division of the Brigham and Women’s Hospital in Boston. He has been elected the National Academy of Medicine(NAM), the American Society for Clinical Investigation, the American Association of Physicians, and the American Pediatric Societies, and is a fellow of the American Academy of Arts and Sciences (AAAS) and the American Association for the Advancement of Science.
Xiang-Dong Fu, PhDDepartment of Cellular and Molecular Medicine, University of California, San Diego
Dr. Fu’s laboratory is interested in molecular and cell biology of RNA metabolism and regulation in higher eukaryotic cells. Current research interests in the Fu lab include the regulation of alternative splicing, functional RNA elements in mammalian genomes, transcription/splicing coupling, nuclear architecture, and cellular reprogramming. Dr. Fu was a major contributor for co-discovery of SR proteins, a family of RNA binding proteins involved in constitutive and alternative pre-mRNA processing. His laboratory was the first to identify a family of kinases specific for SR proteins and demonstrated that these kinases are critical for transducing external and intracellular signals to regulate alternative splicing in the nucleus. Dr. Fu's group elucidated a series of regulatory mechanisms for splice site selection in mammalian cells and developed multiple key technologies for high throughput analysis of gene expression, mRNA isoforms, and genomic interactions. Dr. Fu's current research is focused on integrated regulation of gene expression at transcriptional and post-transcriptional levels. Dr. Fu's contribution to biomedical science has been recognized by selection for the Searle Scholar award (1994) and the Leukemia and Lymphoma Society Scholar award (1997) and election to Fellow of American Association for the Advancement of Science (2010).
Dr. Fu is a Professor of Cellular and Molecular Medicine at University of California, San Diego. Dr. Fu received his MS degree in Virology from Wuhan University, China in 1982, PhD degree in Biochemistry from Case Western Reserve University in 1988 (via the CUSBEA program), and postdoctoral training at Harvard from 1988 to 1992. Dr. Fu joined the faculty of University of California, San Diego in 1992 (Assistant Professor, 1992-1998; Associate Professor, 1998 to 2002; and Full Professor, 2002-present).

Rudolf Jaenisch, PhD
Founding Member of Whitehead InstituteDepartment of Biology, MIT
Dr. Jaenisch lab’s expertise is in epigenetics, reprogramming and stem cells. Dr. Jaenisch began his research career as a pioneer making transgenic mice, some of which have produced important advances in understanding cancer, neurological and connective tissue diseases, and developmental abnormalities. These methods have been used to explore basic questions such as the role of DNA modification, genomic imprinting, X chromosome inactivation, nuclear cloning, and, most recently, the nature of stem cells. In addition, using mice as a model and a technique called “altered nuclear transfer,” Dr. Jaenisch has demonstrated that it is possible to procure embryonic stem cells without harming a viable embryo. More recently he has demonstrated that somatic cells can be reprogrammed in vitro to pluripotent ES-like cells and that these cells are suitable to correct both genetic and induced defects in mice by transplantation therapy. Using this technique for turning skin cells into stem cells, the lab has been able to cure mice of sickle cell anemia -- the first direct proof that these easily obtained cells can reverse an inherited disease.
Dr. Jaenisch is a Professor of Biology at MIT and a founding member of the Whitehead Institute for Biomedical Research. He has been granted numerous awards from organizations across the world. He is a pioneer of transgenic science, in which an animal’s genetic makeup is altered. Jaenisch has focused on creating genetically modified mice to study cancer and neurological diseases. Dr. Jaenisch received his doctorate in medicine from the University of Munich in 1967. He became a postdoc at the Max Planck Institute in Munich, studying bacteriophages. He left Germany in 1970 for research positions at Princeton University, Fox Chase Institute for Cancer Research and the Salk Institute. He returned to Germany in 1977 to become the head of the Department of Tumor Virology at the Heinrich Pette Institute at the University of Hamburg. He arrived at MIT in 1984. He participated in the 2005 science conference on human cloning at the United Nations and serves on the science advisory boards of the Genetics Policy Institute and Stemgent.

Xi He, PhDBoston Children’s Hospital, Harvard Medical School
Dr. He’s laboratory seeks to understand the molecular basis of cell-to-cell communication, and how this communication regulates embryonic and neural development in vertebrates. Dr. He is also interested in learning how defective regulation of cell communication causes human cancers and diseases. In particular, Dr. He is investigating signaling mechanisms employed by secreted growth factors of the Wnt family, which play critical roles in establishing the anterior-posterior axis of the embryo and underlie the formation of head versus trunk regions during early embryogenesis. Wnt signaling pathways are also pivotal in the development of human cancers--as several key Wnt signaling components are encoded by human oncogenes or tumor suppressor genes--and in the pathogenesis of many human diseases, such as osteoporosis and degenerative disorders. Dr. He aims to identify molecular components of Wnt signaling pathways and the mechanisms by which Wnt pathways are activated and governed during embryonic development and human tumorigenesis. 
Dr. He received his bachelor’s degree in engineering at Huazhong University of Science and Technology (HUST), Wuhan, China, and Ph.D. in Dr. Michael G. Rosenfeld’s lab at University of California, San Diego (UCSD). After his postdoctoral training with Dr. Harold Varmus at National Cancer Institute (NCI), Dr. He became an Assistant Professor at Boston Children’s Hospital in 1997. He was promoted to professor in 2007. Dr. He was a Pew Scholar, a Klingenstein Fellow, a W. M. Keck Distinguished Young Scholar and a Leukemia and Lymphoma Society Scholar. Dr. He received the Young Investigator Award from the Society of Chinese Bioscientists in America (SCBA) in 2004, and holds a Chang Jiang Guest Professorship and 1000 Talent Plan (B) Professorship at HUST. Dr. He is an elected Fellow of American Association for the Advancement of Science and an American Cancer Society Research Professor. He has served on numerous review and advisory boards in academia and the biopharmaceutical industry in the USA, Canada, EU, UK and China.

William Pu, MDBoston Children's Hospital, Harvard Medical School
The Pu lab is interested in the regulation of gene expression and cell lineage specification in heart development, disease, and regeneration using various technologies including genetically engineered mice, conditional gene inactivation, genome-wide chromatin occupancy analysis, and RNA expression profiling. The major goals of Dr. Pu's research include: 1. To understand the transcriptional network regulating heart development and disease; 2. To understand cell lineage specification in heart development and regeneration; 3. To understand genetic contributions to congenital heart disease.
Dr. Pu received an MD from Harvard Medical School. He completed his internship, residence, and pediatric cardiology training at Boston Children’s Hospital. Dr. Pu has been an independent PI since 2004 and has an established track record of innovation in cardiovascular biology. Dr. Pu has 19 successful postdoctoral fellow “alumni”. Among those, 12 remain in academic medicine, 11 have faculty appointments, and 8 are PIs of independent research labs in Europe, North America, and China. Dr. Pu is also the contact PI of the Boston Children’s Hospital Department of Cardiology T32 training grant and the Director of Basic and Translational Cardiovascular Research for the Department of Cardiology at Boston Children’s Hospital.

Jean Zhao, PhDDana-Farber Cancer Institute, Harvard Medical School 
Dr. Zhao’s research centers on understanding kinase signaling pathways in cancer. Her laboratory has pioneered a new front for understanding signal transduction by integrating mouse genetics, chemical biology and immunology in the field of translational cancer research. Her productive and insightful work on deciphering the role of PI3-kinase isoforms and the cyclin D1-CDK4/6 pathway in cancer not only addresses important basic science questions, but also has had a significant clinical impact. By providing a mechanistic understanding of the synergies gained for targeting PI3K isoforms and CDK4/6 in combination with immune checkpoint blockade in cancer, her lab has guided the design of current clinical trials of integrating immunotherapy and targeted therapy both here at DFCI and internationally. 
Dr. Jean Zhao is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School (HMS) and Dana-Farber Cancer Institute (DFCI). Dr. Zhao has been widely recognized for her innovation and excellence in the field. After obtaining her Ph.D. degree with honors from Tufts University School of Medicine in Boston, Dr. Zhao completed her postdoctoral training in the laboratory of Dr. Thomas M. Roberts at DFCI. Dr. Zhao began her independent research at HMS and DFCI in 2006. Her honors and awards include the Career Development Awards from NIH/NCI, the V Scholar Award, the Starr Foundation Award and, recently, the Outstanding Investigator Award from NIH/NCI. Dr. Zhao serves as a member on multiple scientific boards and committees, including the Executive Committee for Research and the Committee for Women Faculty at DFCI, the Steering Committee of Breast Cancer at DF/Harvard Cancer Center and the Advisory Council of the National Brain Tumor Society.

Wenyi Wei, PhDBeth Israel Deaconess Medical Center, Harvard Medical School
The major focus of research in Dr. Wei’s laboratory is aimed at understanding how APC and SCF activities contribute towards cell cycle regulation and subsequent tumor formation. More specifically, Dr. Wei is interested in elucidating the underlying mechanisms that define the oscillation of APC and SCF activity in different cell cycle phases. Currently, he is pursuing the underlying mechanisms that timely regulate APC/Cdh1 activity in different cell cycle phases. Additionally, Dr. Wei is also interested in understanding whether other layers of crosstalk between the APC and SCF complex exist. Furthermore, Dr. Wei would like to identify novel downstream targets for both APC and SCF complexes, which will help pinpoint their functions in both cell cycle control and tumor formation. To this end, Dr. Wei has developed biochemical purification approaches that would allow him to identify novel downstream targets for APC/Cdh1 and SCF/Fbw7 complexes. In addition, he is also interested in defining the tumor suppressor function of Cdh1 utilizing conditional Cdh1 knockout mice. To achieve these goals, Dr. Wei’s lab will use multidisciplinary approaches including biochemical and genetic analysis. 
Dr. Wenyi Wei received his B.A. degree from Shandong University in 1993 and then obtained his M.S. training in Chinese Academy of Science from 1993 to 1996. Afterwards Dr. Wei received his Ph.D. training in the Department of Molecular Biology, Cell Biology & Biochemistry (MCB) at Brown University and his postdoctoral training in the laboratory of Dr. William Kaelin, Jr. at DFCI and Harvard Medical School. Dr. Wei became independent from 2006 in Department Pathology at Beth Israel Deaconess Medical Center and Department of Pathology at Harvard Medical School. 

Nathanael Gray, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Dr. Nathanael Gray’s research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance. Dr. Gray has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Amongst the additional notable achievements of Dr. Gray’s research laboratory are: development of the first T790M selective EGFR inhibitors, ATP-competitive mTor inhibitor, Torin1, and its use to discover that rapamycin is an incomplete inhibitor of mTOR; development of the first inhibitors of ERK5 (BMK1), CDK7 and CDK12. 
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. In 2006, Dr. Gray returned to academia and accepted a faculty appointment at the Dana Farber Cancer Institute and Harvard Medical School in Boston. Dr. Gray’s scientific contributions have been recognized through numerous awards including the Career Award of the National Science Foundation in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011.

Jiahuai Wang, PhDDana-Farber Cancer Institute, Harvard Medical School
Dr. Wang’s lab has been focusing on structures of cell surface receptors that play critical roles in the immune system and nervous system. In collaboration with colleagues within Dana-Farber and Harvard Medical School, the Wang lab has worked out structures of a number of key immune molecules, including T cell receptors, MHC molecules, co-receptors and their interacting complexes. His group has also determined structures of many cell adhesion molecules, such as CD2, CD58, Cadherin, ICAM family members and the complexes with their interacting partners. More recently he begins to turn his interests into neuronal receptors. Most recently in collaboration with a group at EMBL, Hamburg, Dr. Wang has determined the structure of netrin-1 in complex with DCC, uncovering the molecular mechanism of netrin-1 bi-functionality, a long-standing puzzle in the neuroscience field.
Dr. Jiahuai Wang obtained his B.A from the University of Science and Technology of China in 1963 and an equivalent Ph.D. from the Beijing Biophysics Institute, Chinese Academy of Sciences in 1979. He had worked in Biophysics Institute in the period of 1963-1979. During 1979-1982, he was a visiting scholar at University of Wisconsin at Madison and at Harvard University, the Department of Biochemistry and Molecular Biology. In 1982-1988 he was back in Beijing Biophysics Institute, promoted to Associate Professor and later Professor. He served as director of Protein Crystallography Department there in 1987-1988. He was appointed as a member of National 863 Committee of Biotechnology of China in 1986-1990. He came to the United States again late in 1988 working at Harvard Medical School, the same department till 1996 before moving to Dana-Farber Cancer Institute as a Principal Investigator. In 2001, he was promoted as an Associate Professor of Pediatrics and Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Xiaoliang Sunney Xie, PhDDepartment of Chemistry and Chemical Biology, Harvard University
Dr. Xiaoliang Sunney Xie received a B.S. from Peking University in 1984, and his Ph.D. from the University of California at San Diego in 1990, followed by a short postdoctoral experience at the University of Chicago. In 1992, Xie joined Pacific Northwest National Laboratory, where he later became a Chief Scientist. In 1999, he was appointed Professor of Chemistry at Harvard University. He was the first full professor at Harvard University from the People's Republic of China since China's reform in 1978. He is currently the Mallinckrodt Professor of Chemistry and Chemical Biology at Harvard, and the Director of Beijing Advanced Innovation Center for Genomics at Peking University.
Xie is among the first to conduct fluorescence studies of single molecules at room temperature in the early 1990s. He has made major contributions to the emergence of the field of single-molecule biophysical chemistry and its application to biology. His team also pioneered the development of coherent Raman scattering microscopy and single cell whole genome sequencing.
His honors include the Albany Prize in Medicine and Biomedical Research, the U. S. Department of Energy E. O. Lawrence Award, the Biophysical Society’s Founders Award, the National Institute of Health Director’s Pioneer Award, the Sackler Prize for Physical Sciences and the American Chemical Society’s Peter Debye Award. Xie is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He is also an honorary fellow of the Chinese Chemical Society and has received scholarly awards from China, Germany and Israel. 

Join us for the day-long discussion with U.S. and Chinese healthcare leaders!

The 7th U.S.-China Health Summit is coming on September 15, at Harvard Medical School! Join us to hear senior managers like the Chief Health Officer of IBM Watson Health, renowned scholars from Harvard and Peking Union Medical College, as well as hospital executives and policy makers discuss important healthcare challenges and opportunities.
This is a great opportunity for those interested in the global healthcare industry. If you want to catch up with latest healthcare trends in U.S. and China, learn more about a career in healthcare, and expand your network with dedicated leaders in healthcare, or if you are just looking for opportunities to broaden your horizons regarding global issues, we sincerely invite you to the 7th U.S.-China Health Summit!

Themed “Megatrends in Health and Healthcare,” the 7th U.S.-China Health Summit will discuss:

1) the changing world and emerging health challenges;
2) megatrends in health and medical sciences and technology; 
3) megatrends in healthcare service innovation.

Confirmed speakers and their speech topics include: 
Ezra Vogel
Henry Ford II Professor of the Social Sciences Emeritus, Harvard University
“From Deng Xiaoping to Xi Jinping: the New Era of China”
Donald Ingber
Founding Director, Harvard Wyss Institute
“Breakthrough Discoveries Cannot Change the World If They Do Not Leave the Lab”
David Blumenthal
President, Commonwealth Fund
“ObamaCare, TrumpCare, and the Future of US Healthcare” 
Yuanli Liu
Dean, Peking Union Medical College School of Public Health
“Public Health Achievements and NCD Challenges in China”
Shaoping Deng
Center of Translational Medicine, the Chinese Academy of Sciences
“China’s Comparative Advantage and Weakness in Medical Research and Translation” 
Steve Chen
Founder and CEO, 
Third-Brain Research Institute

“Supercomputers Grid for Healthcare Cloud and Brain/Cancer Research, Genetics Engineering, Precision Medicine and Cancer Immunology Therapy”
Jingwei Liu
Director of Healthcare Innovation, China Electronic Sciences Inc.
“Developing a People-Centered Active Care Model in China”
Robert Huckman
Professor of Business Administration, Harvard Business School
Making Healthcare a Consumer Product"
Jing Ma
Associate Professor,
Brigham & Women’s Hospital

Why Chinese Doctors are Unhappy? A Report From China
Arthur Kleinman
Professor of Medical Anthropology in Social Medicine, Harvard Medical School
"Mental Health in China in the Context of Global Health"
Randall Moore
President, Mercy Virtual Health
“Virtual Health"
Kyu Rhee
Vice President and Chief Health Officer, IBM Watson Health
"Future of Health is Cognitive"
Peter Juhn
Vice President and Global Head of Value-Based Partnerships, Amgen
“Value-Based Contracting"
Brent James
CTO, Intermountain Healthcare
"Strategies to Lower Costs, Improve Quality, and Engage Patients"
Bill Sibold
CEO, Sanofi Genzyme
(Speech Topic TBD)
Jack Spengler
Akira Yamaguchi Professor, Harvard T.H. Chan School of Public Health
"Cities, Climate Change & Health: A Future Not Informed by the Past"
(Speakers and topics may be subject to slight change as needed.)
More speakers are detailed on our website.

Tickets for different groups (industry, general public and students) are now available on our Eventbrite on a first come, first served basis.
Industry tickets include VIP dinner – a unique chance to talk with Summit speakers & guests and learn more about future opportunities in Chinese healthcare market! 
If you have any questions, feel free to email us at info@uschinahealthsummit.org
and we will reach out to you shortly. We look forward to witnessing with you how U.S. and Chinese healthcare leaders are moving forward together!
About U.S.-China Health Summit

U.S.-China Health Summit (the Summit) has been dedicated to advancing global health by promoting exchange of knowledge, ideas and experiences among the current and future health sector leaders from China, the U.S. and other countries.
The annual Summit has become an important part of the U.S.-China Strategic and Economic Dialogue, as well as the People-To-People Exchange Program. Last year, over 200 scholars, 300 company representatives, 400 government officials and 1,100 hospital executives from both the U.S. and China attended the 6th Summit, discussing a variety of academic, policy and investment topics in 10 forums.




Ezra Vogel
William Haseltine
Arthur Kleinman
Mark Elliott  
Kyu Rhee
IBM Watson Health副总裁兼首席卫生官
Randall Moore
Mercy Virtual Health主席
 David Blumenthal
Robert Huckman
Donald Ingber
Alan Trager
公私伙伴关系倡议创始人兼主任; 清华大学PPP研究中心国际比较研究中心首席专家
Sep 9th (Saturday) 2017, 10am - 2pm
Dana Building 1620, Dana-Farbar Cancer Institute
450 Brookline Ave, Boston, MA 02215
Lunch will be provided

(Cellular BioMedicine Group)
加州 | 马里兰 | 上海 | 无锡 | 北京

Tony Liu, CEO

Yihong Yao, CSO

• 美国加州政府干细胞专项支持机构(CIRM)资助开展的异体人源脂肪干细胞治疗膝骨关节炎(临床试验I/II期)
• 嵌合抗原受体T细胞疗法(CAR-T)治疗急性B淋巴细胞性白血病,非霍奇金淋巴瘤, 多发性骨髓瘤以及各种实体瘤(临床试验I/II期)

Conference Program
8:00 – 9:00
Registration and Breakfast
Opening Remarks
9:00 – 9:10
Mr. Larry Cai, Conference Chair, SAPA-NE President-Elect
Hon. Deval Patrick, Governor, Massachusetts (2007-2015)
Mr. Jijun Xing, Counselor of S&T, Consulate General of P. R. China
Session 1: Cutting Edge of Biomedical Innovation in Boston
Chairs: Drs. Jun Johnny Yang, Xingfeng Bao, Kejie Li, Lin Lin, Jing Tong
9:10 – 9:45
Dr. Andy Plump, Chief Medical and Scientific Officer, Takeda
“The Future of Drug Discovery: Innovation-driven Research & Development at Takeda”
9:45 – 10:20
Dr. Richard Murray, CEO and President, Jounce Therapeutics
“Immunology meets oncology: breakthroughs in immunotherapy”
10:20 – 10:50
Coffee Break and Exhibition
10:50 – 11:25
Dr. Sven Ante “Bill” Lundberg, CSO, CRISPR Therapeutics
“Bringing CRISPR Therapeutics to the Clinic”
11:25 – 11:50
Dr. Luhan Yang, CSO, eGenesis
“Gene Editing to Transform Xenotransplantation”
11:50 – 12:10
Dr. James Yang, President/CEO of Abpro China
“Fast Road Map for Biologic R&D”
12:10 – 1:00
Lunch and Exhibition
Session 2: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Mangeng Cheng, Dapeng Chen, Haishan Li, and Bing Ma
1:00 – 1:20
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery”
1:20 – 1:40
Dr. Shidong Jia, Founder & CEO, Predicine Holdings Ltd.
“Precision medicine: clinical application of liquid biopsies in cancer”
1:40 – 2:00
Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
“Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs”
2:00 – 2:20
Ms. Jane Li, Co-founder, AF Recruiting
“Landscape of Healthcare Job Market in China”
Panel Forum: Collaborations and Opportunities Across the Ocean
Chairs: Drs. Tianxiao Sun and QiYing Hu
2:20 – 3:20
Dr. Shaohui Huang, Zhongshan Tsuihang New District
Dr. Ruhong Jiang, Applied Stemcell
Dr. Jinbo Lee, Scilligence
Dr. John MacDougall, CrownBio
Dr. Weimin Tang, Hengrui Therapeutics Inc.
Dr. Tony Xie, Xiyu Investment Company
3:20 – 3:50
Coffee Break and Exhibition
Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences
Chairs: Mr. Larry Cai, Drs. Guiqing Liang and Jianzhu Chen
3:50 – 4:20
Dr. Lijun Wu, Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
“From Seed to Exit in 15 Months: The Delinia Story”
4:20 – 4:50
Dr. Yinxiang Wang, Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Zhejiang Betta Pharmaceuticals
“Challenges and Strategies of Innovative Drug R&D in China”
4:50 – 5:25
Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
“Follow the Science and Capture the Opportunities”
5:25 – 5:30
Closing Remark: Dr. Jiang Long, President of SAPA-NE
SAPA-NE 19th Annual Conference Dinner Reception (Ticket Required)
Sponsored by Greenberg & Traurig, LLP
(Location: Samberg Conference Center, 50 Memorial Drive, Cambridge MA)
Chair: Dr. Jiang Long, President of SAPA-NE
6:00 – 6:30

6:30 – 6:35

6:35 – 6:45

6:45 – 7:00

7:00 – 7:10

7:10 – 9:00
GT HomeNetworking

Welcome Remarks
Dr. Jiang Long, President of SAPA-NE

Keynote Speech
Dr. Fang Xie, Co-lead, Global Life Science, Greenburg Traurig, LLP
“Convergence of Law and Biopharma”

SAPA-NE Cooperate Service Award/Service Award Presentations
Dr. Jiang Long and Mr. Larry Cai/ Drs. Bingli Ma, Mark Lin, Xiaotian Zhong, Min Chen

SAPA-NE High School Excellence Scholarship Presentation
Drs. Huo Li and Guiqing Liang


Opening Remark
Session 1: Cutting Edge of Biomedical Innovation in Boston

Andy Plump, MD, PhD Chief Medical and Scientific Officer, Takeda Pharmaceuticals
Presentation title: The Future of Drug Discovery: Innovation-driven Research & Development at Takeda

Richard Murray, Ph.D., Chief Executive Officer and President
Presentation title: Immunology meets oncology: breakthroughs in immunotherapy

Dr. Sven Ante “Bill” Lundberg, Chief Scientific Officer, CRISPR Therapeutics
Presentation title: Bringing CRISPR Therapeutics to the Clinic

LUHAN YANG, Ph.D., Co-Founder and CSO
Presentation title: “Gene Editing to Transform Xenotransplantation

James Yang, Ph.D., President and CEO, Abpro-China
Presentation title: “Fast Road Map for Biologic R&D

Session 2: Collaborations and Opportunities Across the Ocean
Dr. Rich Soll, SVP & Head of International Discovery Services Unit (IDSU)
Presentation title: Enter the Era of Big Data, Deep Learning, and Artificial Intelligence: Capitalizing on a Transformative Opportunity for Drug Discovery
Shidong Jia, Ph.D., Founder & CEO, Predicine Holdings Ltd
Displaying image1.JPGPresentation title: “Precision medicine: clinical application of liquid biopsies in cancer”

Chaoshe Guo, Ph.D., Vice President and Senior R&D Director, Beijing Biocytogen Co.,Ltd
Presentation Title: Humanized immune checkpoint mouse models and in vivo efficacy studies of I/O drugs

Ms. Jane Li,
Co-founder of AF Recruiting
Presentation title: Landscape of Healthcare Job Market in China

Panel Forum: Collaborative Innovation and Partnership

Shaohui Huang, Ph.D., Business Consultant, Zhongshan Tsuihang New District; President & Co-Founder, LightEdge Technologies, Ltd.; Professor, Institute of Biophysics, Chinese Academy of Sciences

Applied StemCell
Ruhong Jiang, Ph.D.,
Co-founder, President and CEO, Applied StemCell, Inc.

Jinbo Lee, Ph.D., Co-founder and Chief Scientific Officer of Scilligence Corporation

John MacDougall, Ph.D., Director of Scientific Engagement, CrownBio

Image result for jiangsu hengrui medicine
Weimin Tang, Ph.D., Head of BD, Jiangsu Hengrui Medicine Co.


Mr. Shuijiang Zhou, Founder, Xiyu Investment Company

Session 3: Entrepreneurship and Global Leadership in Biomedical Sciences

Lijun Wu, Ph.D., Entrepreneur-in-Residence, Atlas Venture, former SVP, Preclinical & Early Clinical Development, Delinia, Inc
Presentation title: “From Seed to Exit in 15 Months: The Delinia Story”

Beijing Jacobio Pharmaceuticals Co.,Ltd
Yinxiang Wang, Ph.D., Chairman, Beijing JacoBio Pharmaceuticals, former CEO & CSO, Betta Pharmaceuticals
Presentation title: Challenges and Strategies of Innovative Drug R&D in China

Dr. Yong-Jun Liu, Head of Research, Global R&D, Sanofi
 Presentation title: Follow the Science and Capture the Opportunities

Dinner Reception Keynote Speech
Dinner Keynote Speaker:
Fang Xie, Ph.D.
Of Counsel, Co-lead, Global Life Sciences, Greenberg Traurig, LLP, Boston

Presentation title: The Convergence of Law and Biopharma”

No comments: